ЕРЛОТИНІБ-МІЛІ-25

उत्पाद अवलोकन

About ЕРЛОТИНІБ-МІЛІ-25

ЕРЛОТИНІБ-МІЛІ-25 is a prescription medication containing the active ingredient Erlotinib, a tyrosine kinase inhibitor used in the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. It is available in a tablet form for oral administration.

Key Benefits & Uses

• Treatment of non-small cell lung cancer (NSCLC) in patients with specific EGFR mutations
• Treatment of pancreatic cancer in patients with specific EGFR mutations
• Monotherapy for patients with locally advanced or metastatic NSCLC who have failed other treatments

Active Ingredient & Action

Erlotinib works by inhibiting the epidermal growth factor receptor (EGFR) tyrosine kinase, which is involved in the growth and spread of cancer cells. By blocking this enzyme, Erlotinib helps to slow down the growth of cancer cells and prevent their spread.

Important Notes

ЕРЛОТИНІБ-МІЛІ-25 should only be used under the guidance of a qualified healthcare professional. Patients should be aware of the potential side effects, including skin rash, diarrhea, and liver damage. Regular monitoring of liver function and skin health is recommended. It is essential to follow the prescribed dosage and administration instructions carefully.